Kane Biotech Inc.
$200,000.00 CAD
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2024-2025
- Agreement period
- August 1, 2024 – March 31, 2026
- Reference
- nrc-cnrc:172-2024-2025-Q2-1021203
Published purpose
The Design and Development of products based on the revyve Antimicrobial Wound Gel. The sterile wound gel, primarily intended to be used in surgical rooms for post surgery infection prevention; the spray wound gel, primarily intended to be used for large surface burn wounds to clear any existing infection and protect from subsequent infection. Application and removal wound be contactless for these sensitive wounds; and the wound cleanser that is intended to be used prior to debridement and treatment with the revyve wound gel as part of a wound management regimen. The project involves all stages of development for all products, from conception to design transfer.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.